Acrivon Therapeutics, Inc.
ACRV
$1.49
-$0.155-9.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -22.83M | -22.44M | -18.80M | -16.49M | -19.25M |
| Total Depreciation and Amortization | 303.00K | 251.00K | 228.00K | 224.00K | 149.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.05M | 2.70M | 2.70M | 2.99M | 2.57M |
| Change in Net Operating Assets | 2.12M | 2.16M | 1.97M | -3.81M | 4.17M |
| Cash from Operations | -17.36M | -17.32M | -13.90M | -17.08M | -12.37M |
| Capital Expenditure | -827.00K | -989.00K | -137.00K | -815.00K | -1.15M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.24M | 17.00M | -87.91M | 6.67M | 21.69M |
| Cash from Investing | 14.41M | 16.01M | -88.04M | 5.85M | 20.54M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 70.01M | 79.00K | 318.00K |
| Repurchase of Common Stock | -647.00K | -1.20M | -510.00K | -166.00K | -1.30M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -307.00K | 53.85M | -85.00K | -1.03M |
| Cash from Financing | -647.00K | -1.50M | 123.35M | -172.00K | -2.01M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.60M | -2.82M | 21.40M | -11.41M | 6.16M |
